WO2015015118A3 - NOUVELLES FORMES DE CO-CRISTAUX D'AGOMELATINE ET D'ACIDE p-TOLUENESULFONIQUE, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT - Google Patents

NOUVELLES FORMES DE CO-CRISTAUX D'AGOMELATINE ET D'ACIDE p-TOLUENESULFONIQUE, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT Download PDF

Info

Publication number
WO2015015118A3
WO2015015118A3 PCT/FR2014/051972 FR2014051972W WO2015015118A3 WO 2015015118 A3 WO2015015118 A3 WO 2015015118A3 FR 2014051972 W FR2014051972 W FR 2014051972W WO 2015015118 A3 WO2015015118 A3 WO 2015015118A3
Authority
WO
WIPO (PCT)
Prior art keywords
agomelatine
pharmaceutical compositions
crystals
same
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2014/051972
Other languages
English (en)
Other versions
WO2015015118A2 (fr
Inventor
Hanbin Shan
Yuhui SHEN
Ying Luo
Philippe Letellier
Michael Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Pharmaceutical Industry
Les Laboratoires Servier SAS
Original Assignee
Shanghai Institute of Pharmaceutical Industry
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2013/080472 external-priority patent/WO2015013903A1/fr
Priority claimed from FR1360121A external-priority patent/FR3012141B1/fr
Priority to JP2016530589A priority Critical patent/JP6525996B2/ja
Priority to HK16111559.2A priority patent/HK1223348A1/zh
Priority to ES14749937T priority patent/ES2734562T3/es
Priority to EA201600143A priority patent/EA031053B1/ru
Priority to HRP20191119TT priority patent/HRP20191119T1/hr
Priority to RS20190633A priority patent/RS58778B1/sr
Priority to HK16110305.1A priority patent/HK1222167B/xx
Priority to MEP-2019-153A priority patent/ME03388B/fr
Priority to LTEP14749937.0T priority patent/LT3036218T/lt
Priority to EP14749937.0A priority patent/EP3036218B1/fr
Priority to NZ716153A priority patent/NZ716153A/en
Priority to SI201431215T priority patent/SI3036218T1/sl
Priority to MX2016001218A priority patent/MX369301B/es
Priority to RU2016106954A priority patent/RU2695609C2/ru
Priority to UAA201601716A priority patent/UA117023C2/uk
Application filed by Shanghai Institute of Pharmaceutical Industry, Les Laboratoires Servier SAS filed Critical Shanghai Institute of Pharmaceutical Industry
Priority to KR1020167004728A priority patent/KR20160035598A/ko
Priority to AU2014298230A priority patent/AU2014298230C1/en
Priority to CA2918228A priority patent/CA2918228C/fr
Priority to PL14749937T priority patent/PL3036218T3/pl
Priority to CN201480042990.3A priority patent/CN105473551B/zh
Priority to US14/908,253 priority patent/US9663451B2/en
Priority to SG11201600005VA priority patent/SG11201600005VA/en
Priority to DK14749937.0T priority patent/DK3036218T3/da
Publication of WO2015015118A2 publication Critical patent/WO2015015118A2/fr
Publication of WO2015015118A3 publication Critical patent/WO2015015118A3/fr
Priority to ZA2016/00196A priority patent/ZA201600196B/en
Anticipated expiration legal-status Critical
Priority to CY20191100686T priority patent/CY1122959T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouvelles formes de co-cristaux d'agomélatine et d'acide p-toluènesulfonique, leur procédé de préparation ainsi que les compositions pharmaceutiques qui les contiennent. Les co-cristaux selon l'invention présentent une meilleure solubilité que l'agomélatine et sont donc plus appropriés pour l'élaboration de compositions pharmaceutiques. Ils présentent de plus une bonne stabilité et pureté, et sont par ailleurs obtenus par un procédé simple, ne comportant aucune étape difficile.
PCT/FR2014/051972 2013-07-31 2014-07-30 NOUVELLES FORMES DE CO-CRISTAUX D'AGOMELATINE ET D'ACIDE p-TOLUENESULFONIQUE, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT Ceased WO2015015118A2 (fr)

Priority Applications (25)

Application Number Priority Date Filing Date Title
KR1020167004728A KR20160035598A (ko) 2013-07-31 2014-07-30 아고멜라틴 및 p-톨루엔설폰산의 공결정의 신규한 형태, 이를 제조하기 위한 방법 및 이를 함유하는 약학적 조성물
DK14749937.0T DK3036218T3 (da) 2013-07-31 2014-07-30 Co-krystaller af agomelatin og p-toluensulfonsyre, fremgangsmåde til deres fremstilling og lægemiddelsammen-sætninger indeholdende disse
UAA201601716A UA117023C2 (uk) 2013-07-31 2014-07-30 КРИСТАЛІЧНІ ФОРМИ СПІВКРИСТАЛІВ АГОМЕЛАТИНУ ТА p-ТОЛУОЛСУЛЬФОНОВОЇ КИСЛОТИ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ, ЯКІ ЇХ МІСТЯТЬ
ES14749937T ES2734562T3 (es) 2013-07-31 2014-07-30 Co-cristales de agomelatina y ácido p-toluensulfónico, su procedimiento de preparación y composiciones farmacéuticas que los contienen
EA201600143A EA031053B1 (ru) 2013-07-31 2014-07-30 Новые формы сокристаллов агомелатина и п-толуолсульфоновой кислоты, способ их получения и фармацевтические композиции, которые их содержат
HRP20191119TT HRP20191119T1 (hr) 2013-07-31 2014-07-30 Ko-kristali agomelatina i p-toluensulfonske kiseline, način pripreme i i farmaceutski pripravci koji sadržavaju iste
RS20190633A RS58778B1 (sr) 2013-07-31 2014-07-30 Ko-kristali agomelatina i p-toluensulfonske kiseline, postupak za njihovu proizvodnju i farmaceutske kompozicije koje ih sadrže
HK16110305.1A HK1222167B (en) 2013-07-31 2014-07-30 Novel forms of co-crystals of agomelatine and p-toluenesulphonic acid, method for preparing same and the pharmaceutical compositions containing same
MEP-2019-153A ME03388B (fr) 2013-07-31 2014-07-30 NOUVELLES FORMES DE CO-CRISTAUX D'AGOMELATINE ET D'ACIDE p-TOLUENESULFONIQUE, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
LTEP14749937.0T LT3036218T (lt) 2013-07-31 2014-07-30 Agomelatino ir p-toluensulfonrūgšties monohidrato bendri kristalai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos
EP14749937.0A EP3036218B1 (fr) 2013-07-31 2014-07-30 Co-cristaux d'agomelatine et d'acide p-toluenesulfonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ716153A NZ716153A (en) 2013-07-31 2014-07-30 Novel forms of co-crystals of agomelatine and p-toluenesulphonic acid, method for preparing same and the pharmaceutical compositions containing same
SI201431215T SI3036218T1 (sl) 2013-07-31 2014-07-30 Kokristali agomelatina in P-toluenesulfonske kisline, postopek za njihovo pripravo in farmacevtski sestavki, ki jih vsebujejo
MX2016001218A MX369301B (es) 2013-07-31 2014-07-30 Nuevas formas de co-cristales de agomelatina y de acido p-toluenosulfonico, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
RU2016106954A RU2695609C2 (ru) 2013-07-31 2014-07-30 НОВЫЕ ФОРМЫ СОКРИСТАЛЛОВ АГОМЕЛАТИНА И n-ТОЛУОЛСУЛЬФОНОВОЙ КИСЛОТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, КОТОРЫЕ ИХ СОДЕРЖАТ
JP2016530589A JP6525996B2 (ja) 2013-07-31 2014-07-30 アゴメラチンとｐ−トルエンスルホン酸との新規な形態の共結晶、これらの製造方法及びこれらを含有する医薬組成物
CN201480042990.3A CN105473551B (zh) 2013-07-31 2014-07-30 阿戈美拉汀和对甲苯磺酸的共晶的新形式、其制备方法和包含其的药物组合物
SG11201600005VA SG11201600005VA (en) 2013-07-31 2014-07-30 Novel forms of co-crystals of agomelatine and p-toluenesulphonic acid, method for preparing same and the pharmaceutical compositions containing same
AU2014298230A AU2014298230C1 (en) 2013-07-31 2014-07-30 Novel forms of co-crystals of agomelatine and p-toluenesulphonic acid, method for preparing same and the pharmaceutical compositions containing same
CA2918228A CA2918228C (fr) 2013-07-31 2014-07-30 Nouvelles formes de co-cristaux d'agomelatine et d'acide p-toluenesulfonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PL14749937T PL3036218T3 (pl) 2013-07-31 2014-07-30 Ko-kryształy agomelatyny i kwasu p-toluenosulfonowego, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
HK16111559.2A HK1223348A1 (zh) 2013-07-31 2014-07-30 阿戈美拉汀和对甲苯磺酸的共晶的新形式、其制备方法和包含其的药物组合物
US14/908,253 US9663451B2 (en) 2013-07-31 2014-07-30 Forms of co-crystals of agomelatine and p toluenesulphonic acid, a process for their preparation and pharmaceutical compositions containing them
ZA2016/00196A ZA201600196B (en) 2013-07-31 2016-01-11 NEW AGOMELATINE p-TOLUENESULFONIC ACID CO-CRYSTAL FORMS AND PREPARATION THREOF
CY20191100686T CY1122959T1 (el) 2013-07-31 2019-07-01 Συν-κρυσταλλοι αγομελατινης και π-τολουολοσουλφονικου οξεος, μεθοδος για την παρασκευη αυτων και οι φαρμακευτικες συνθεσεις αυτων

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/080472 2013-07-31
PCT/CN2013/080472 WO2015013903A1 (fr) 2013-07-31 2013-07-31 Nouvelles formes de co-cristaux d'agomélatine et d'acide p-toluènesulfonique et leur préparation
FR13/60121 2013-10-17
FR1360121A FR3012141B1 (fr) 2013-10-17 2013-10-17 Nouvelles formes de co-cristaux d'agomelatine et d'acide p-toluenesulfonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
WO2015015118A2 WO2015015118A2 (fr) 2015-02-05
WO2015015118A3 true WO2015015118A3 (fr) 2015-04-02

Family

ID=51300781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2014/051972 Ceased WO2015015118A2 (fr) 2013-07-31 2014-07-30 NOUVELLES FORMES DE CO-CRISTAUX D'AGOMELATINE ET D'ACIDE p-TOLUENESULFONIQUE, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

Country Status (25)

Country Link
US (1) US9663451B2 (fr)
EP (1) EP3036218B1 (fr)
JP (1) JP6525996B2 (fr)
CN (1) CN105473551B (fr)
AU (1) AU2014298230C1 (fr)
CA (1) CA2918228C (fr)
CY (1) CY1122959T1 (fr)
DK (1) DK3036218T3 (fr)
EA (1) EA031053B1 (fr)
ES (1) ES2734562T3 (fr)
HK (1) HK1223348A1 (fr)
HR (1) HRP20191119T1 (fr)
HU (1) HUE044798T2 (fr)
LT (1) LT3036218T (fr)
ME (1) ME03388B (fr)
MX (1) MX369301B (fr)
NZ (1) NZ716153A (fr)
PL (1) PL3036218T3 (fr)
PT (1) PT3036218T (fr)
RS (1) RS58778B1 (fr)
RU (1) RU2695609C2 (fr)
SG (1) SG11201600005VA (fr)
SI (1) SI3036218T1 (fr)
UA (1) UA117023C2 (fr)
WO (1) WO2015015118A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702041A (zh) * 2012-05-14 2012-10-03 上海右手医药科技开发有限公司 阿戈美拉汀苯磺酸类复合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498466B2 (en) * 2004-02-13 2009-03-03 Les Laboratoires Servier Process for the synthesis and crystalline form of agomelatine
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
EP2517700B1 (fr) * 2011-04-28 2013-07-17 Zentiva, k.s. Cocristaux pharmaceutiquement acceptables de la N-[2-(7-méthoxy-1-naphthyl)éthyl]acetamide et méthodes de leur préparation
PH12012000132B1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102503886B (zh) * 2011-10-11 2013-09-11 中山大学 阿戈美拉汀-异烟碱共晶及其组合物和制备方法
KR20150020191A (ko) 2012-05-14 2015-02-25 상하이 라이트핸드 팜테크 주식회사 아고멜라틴 산기 복합체와 그의 제조방법 및 용도
CN102702008B (zh) * 2012-06-03 2014-05-28 上海右手医药科技开发有限公司 阿戈美拉汀硫酸复合物及其制备方法
CN102718676B (zh) * 2012-06-26 2014-04-09 福建广生堂药业股份有限公司 阿戈美拉汀硫酸盐及其制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702041A (zh) * 2012-05-14 2012-10-03 上海右手医药科技开发有限公司 阿戈美拉汀苯磺酸类复合物及其制备方法

Also Published As

Publication number Publication date
NZ716153A (en) 2020-08-28
PL3036218T3 (pl) 2019-09-30
HUE044798T2 (hu) 2019-11-28
SG11201600005VA (en) 2016-02-26
AU2014298230B2 (en) 2018-07-26
LT3036218T (lt) 2019-05-27
CN105473551A (zh) 2016-04-06
WO2015015118A2 (fr) 2015-02-05
JP6525996B2 (ja) 2019-06-05
CY1122959T1 (el) 2021-10-29
EP3036218B1 (fr) 2019-04-10
EP3036218A2 (fr) 2016-06-29
RU2695609C2 (ru) 2019-07-24
CN105473551B (zh) 2019-01-11
US20160168077A1 (en) 2016-06-16
RS58778B1 (sr) 2019-06-28
EA031053B1 (ru) 2018-11-30
AU2014298230A1 (en) 2016-02-04
AU2014298230C1 (en) 2018-11-08
SI3036218T1 (sl) 2019-06-28
EA201600143A1 (ru) 2016-11-30
PT3036218T (pt) 2019-06-11
US9663451B2 (en) 2017-05-30
MX369301B (es) 2019-11-05
RU2016106954A3 (fr) 2018-06-01
DK3036218T3 (da) 2019-07-15
UA117023C2 (uk) 2018-06-11
HRP20191119T1 (hr) 2019-10-18
HK1222167A1 (zh) 2017-06-23
MX2016001218A (es) 2016-05-26
HK1223348A1 (zh) 2017-07-28
CA2918228A1 (fr) 2015-02-05
ES2734562T3 (es) 2019-12-10
RU2016106954A (ru) 2017-09-04
JP2016525567A (ja) 2016-08-25
CA2918228C (fr) 2019-05-07
ME03388B (fr) 2020-01-20

Similar Documents

Publication Publication Date Title
EA201890124A1 (ru) Новые гидроксикислотные производные, способ их получения и фармацевтические композиции, содержащие их
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
EA201401292A3 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
JO3155B1 (ar) معدِّل نكهة حلوة
WO2015195656A3 (fr) Synthèse de composés de carbamoylpyridone polycycliques
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
EA201891384A1 (ru) Жидкие препаративные формы, содержащие протиоконазол
MX2017009028A (es) Formas cristalinas novedosas de maleato de neratinib y procedimiento de preparacion de las mismas.
EA201490756A1 (ru) Разагилина цитрамид
HUE052833T2 (hu) Eljárás 2,5-furándikarbonsav (FDCA) elõállítására
PH12016502050B1 (en) Homovanillinic acid ester, in particular, for creating a hot and/or pungent taste sensation
EP3255030A4 (fr) Procédé de production d'acide acrylique
EA201391721A1 (ru) Способ получения полиморфной формы i эторикоксиба
WO2015052568A3 (fr) Formes solides de curcumine et de dérivés de curcumine
WO2016142819A3 (fr) Nouveau procédé de préparation de ranolazine
WO2015097717A3 (fr) Procédé amélioré de préparation de β-carotène
PY1115670A (es) Proceso para la preparación de amidas de ácido pirazolcarboxílico.
WO2015111004A3 (fr) Méthode améliorée de préparation de chlorophényl-trifluoroéthanone
EP4282973A3 (fr) Procédés de préparation pour dérivés de pyrmidinecyclopentane
WO2017093866A3 (fr) Procédé de préparation amélioré de carmin d'indigo
EP3492479A3 (fr) Cristal de sel de sodium d'acide phosphonique cyclique et son procédé de fabrication
WO2013046233A3 (fr) Procédé de préparation d'acétate d'octréotide
MX358995B (es) Forma amorfa estabilizada de agomelatina, un proceso para su preparación y composiciones farmacéuticas que la contienen.
NZ716153A (en) Novel forms of co-crystals of agomelatine and p-toluenesulphonic acid, method for preparing same and the pharmaceutical compositions containing same
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480042990.3

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2918228

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2014749937

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/001218

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 14908253

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2016530589

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014298230

Country of ref document: AU

Date of ref document: 20140730

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20167004728

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201601716

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201600143

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2016106954

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14749937

Country of ref document: EP

Kind code of ref document: A2